Clinical Trials Directory

Trials / Completed

CompletedNCT00716079

The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial

An International Randomised Controlled Trial to Establish the Effects of Early Intensive Blood Pressure Lowering in Patients With Intracerebral Haemorrhage.

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
2,839 (actual)
Sponsor
The George Institute · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this academic lead study is to determine if a treatment strategy of early intensive blood pressure (BP) lowering compared to conservative BP lowering policy in patients with elevated blood pressure within 6 hours of acute intracerebral haemorrhage (ICH) improves the outcome of death and disability at 3 months after onset.

Detailed description

Intracerebral haemorrhage (ICH) is one of the most serious subtypes of stroke, affecting over a million people worldwide each year, most of whom live in Asia. About one third of people with ICH die early after onset and the majority of survivors are left with major long-term disability. Despite the magnitude of the disease burden and cost on healthcare resources, there remains uncertainty about the role of surgery for ICH and no acute medical therapies have been shown to definitely alter outcome in ICH. The INTERACT2 study follows the recently completed initial pilot study vanguard phase) which established the feasibility of the protocol, safety of early intensive BP lowering, and effects on haematoma expansion within 6 hours of onset of ICH. Having established 'proof-of-concept' that BP lowering may improve outcome by reducing haematoma expansion, INTERACT2 aims to establish the effects of the treatment on major clinical endpoints in patients with ICH recruited from an expanding clinical network around the world.

Conditions

Interventions

TypeNameDescription
OTHERBlood pressure management policiesThe trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.

Timeline

Start date
2008-09-01
Primary completion
2012-12-01
Completion
2012-12-01
First posted
2008-07-16
Last updated
2013-12-13
Results posted
2013-10-28

Locations

62 sites across 19 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Chile, China, Finland, France, Germany, Hong Kong, India, Italy, Pakistan, Portugal, Spain, Switzerland, United Kingdom

Source: ClinicalTrials.gov record NCT00716079. Inclusion in this directory is not an endorsement.